Propagermanium
Alternative Names: Proxigermanium; Serocion; SK 818Latest Information Update: 12 Jan 2022
At a glance
- Originator Sanwa Kagaku Kenkyusho
- Developer Astellas Pharma; Sanwa Kagaku Kenkyusho
- Class Antivirals; Organometallic compounds; Small molecules
- Mechanism of Action Immunomodulators; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis B
- No development reported Crohn's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Crohn's-disease in Japan
- 01 Mar 2012 Preclinical trials in Crohn's disease in Japan (unspecified route)
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma